S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:INO

Inovio Pharmaceuticals Stock Forecast, Price & News

$6.74
-0.30 (-4.26 %)
(As of 10/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$6.58
$6.95
50-Day Range
$6.36
$9.69
52-Week Range
$5.81
$19.00
Volume4.07 million shs
Average Volume8.58 million shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.62
30 days | 90 days | 365 days | Advanced Chart
Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Inovio Pharmaceuticals logo

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INO
Employees
262
Year Founded
1979

Sales & Book Value

Annual Sales
$7.41 million
Book Value
$2.47 per share

Profitability

Net Income
$-166.41 million
Net Margins
-2,193.30%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$1.42 billion
Next Earnings Date
11/8/2021 (Estimated)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

1.73 out of 5 stars

Medical Sector

872nd out of 1,358 stocks

Surgical & Medical Instruments Industry

88th out of 124 stocks

Analyst Opinion: 3.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

Is Inovio Pharmaceuticals a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Inovio Pharmaceuticals?

Wall Street analysts have given Inovio Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inovio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Inovio Pharmaceuticals' next earnings date?

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Inovio Pharmaceuticals
.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its quarterly earnings data on Monday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.14. The biopharmaceutical company earned $0.27 million during the quarter, compared to analyst estimates of $1.21 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 42.42% and a negative net margin of 2,193.30%. The company's revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.83) EPS.
View Inovio Pharmaceuticals' earnings history
.

How has Inovio Pharmaceuticals' stock price been impacted by Coronavirus?

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INO shares have decreased by 19.5% and is now trading at $6.74.
View which stocks have been most impacted by COVID-19
.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for INO?

7 analysts have issued 1-year price objectives for Inovio Pharmaceuticals' stock. Their forecasts range from $6.00 to $35.00. On average, they anticipate Inovio Pharmaceuticals' stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the following people:
  • J. Joseph Kim, President, Chief Executive Officer & Director
  • Jacqueline E. Shea, Chief Operating Officer & Executive Vice President
  • Peter D. Kies, Chief Financial Officer
  • Stephen Kemmerrer, Senior Vice President-Engineering Development
  • Kate E. Broderick, Senior Vice President-Research & Development

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.03%) and Greenwich Wealth Management LLC (0.02%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals
.

Which institutional investors are buying Inovio Pharmaceuticals stock?

INO stock was purchased by a variety of institutional investors in the last quarter, including Greenwich Wealth Management LLC, and Green Alpha Advisors LLC.
View insider buying and selling activity for Inovio Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $6.74.

How much money does Inovio Pharmaceuticals make?

Inovio Pharmaceuticals has a market capitalization of $1.42 billion and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166.41 million in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Inovio Pharmaceuticals have?

Inovio Pharmaceuticals employs 262 workers across the globe.

When was Inovio Pharmaceuticals founded?

Inovio Pharmaceuticals was founded in 1979.

What is Inovio Pharmaceuticals' official website?

The official website for Inovio Pharmaceuticals is www.inovio.com.

Where are Inovio Pharmaceuticals' headquarters?

Inovio Pharmaceuticals is headquartered at 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at (267) 440-4200 or via email at [email protected].


This page was last updated on 10/23/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.